Skip to main content
Equibles
SRPT logo

SRPT · Sarepta Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track SRPT — free

Use SRPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SRPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.22 -0.42 (-2.25%) At close · Sep 30
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.97B
Shares
105.63M
Volume · Sep 30 2M Avg daily vol (3M) 3.07M

Sarepta Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Sarepta Therapeutics, Inc. (SRPT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲21.6% $230.27M −$257.74M '22 Q3 22-09-30 ▲28.3% $258.43M −$109.24M '22 Q4 23-01-09 ▲20.2% $253.50M −$516.75M '23 Q1 23-03-31 ▲11.9% $261.24M −$23.94M '23 Q2 23-06-30 ▲44.1% $331.82M −$40.94M '23 Q3 23-09-30 ▲53.5% $396.78M $45.66M '23 Q4 24-01-08 ▲63.1% $413.46M $36.12M '24 Q1 24-03-31 ▲38.9% $362.93M $6.46M '24 Q2 24-06-30 ▲40.8% $467.17M $33.61M '24 Q3 24-09-30 ▲65.9% $658.41M $159.05M '24 Q4 25-02-26 ▲80.2% $744.86M −$447.51M '25 Q1 25-03-31 ▲68.4% $611.09M $196.89M '25 Q2 25-07-16 ▼14.5% $399.36M −$50.57M '25 Q3 25-11-03 ▼32.7% $442.93M −$412.23M '25 Q4 26-02-25 ▼1.9% $730.80M $330.96M '26 Q1 26-05-06 LATEST ▼34.3% $401.25M −$4.89M '26 Q2 26-08-05
Conference
Investor event
2026-09-14
Sarepta Therapeutics, Inc. (SRPT) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
Positive tone FSHD and DM1 readouts siRNA pipeline Elevidys regulatory submissions
Revenue
$401.25M
▼ 34.3% YoY
Diluted EPS
$-0.05
▼ 102.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Sarepta Therapeutics, Inc. (SRPT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Positive tone siRNA pipeline (FSHD and DM1) Alevitus commercial stabilization and growth Alevitus clinical evidence and disease modification
Revenue
$730.80M
▼ 1.9% YoY
Diluted EPS
$2.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-03
Sarepta Therapeutics, Inc. (SRPT) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Positive tone ELEVIDYS Commercial Initiatives & Guidance Pipeline (siRNA Programs) PMO Therapies (AMONDYS, VYONDYS, EXONDYS)
Revenue
$442.93M
▼ 32.7% YoY
Diluted EPS
$-3.93
▼ 362% YoY
Gross margin
-6.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-12
Sarepta Therapeutics, Inc. (SRPT) January 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-03
Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript
Positive tone ESSENCE confirmatory trial results COVID impact on trial data Accelerated to traditional approval transition
Revenue
$399.36M
▼ 14.5% YoY
Diluted EPS
$-0.50
▼ 247.1% YoY
Gross margin
54.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-16
Sarepta Therapeutics, Inc. (SRPT) Q2 2025 Earnings Call Transcript
Balanced tone ELEVIDYS label and safety update Portfolio refocus and pipeline ELEVIDYS revenue stress test
Revenue
$611.09M
▲ 68.4% YoY
Diluted EPS
$1.89
▲ 2600% YoY
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
Cautious tone ELEVIDYS launch and guidance revision Patient safety event and liver failure Site capacity and top-site imbalance
Revenue
$744.86M
▲ 80.2% YoY
Diluted EPS
$-4.60
▼ 1343.2% YoY
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
Confident tone ELEVIDYS launch and commercial performance Financial performance and 2025 guidance LGMD franchise pipeline
Revenue
$658.41M
▲ 65.9% YoY
Diluted EPS
$1.50
Gross margin
76.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
Confident tone ELEVIDYS commercial performance PMO franchise (EXONDYS, VYONDYS, AMONDYS) Guidance and 2025 outlook
Revenue
$467.17M
▲ 40.8% YoY
Diluted EPS
$0.34
Gross margin
72.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript
Confident tone ELEVIDYS label expansion and launch Roche partnership and ex-US approvals PMO franchise (Exondys, Vyondys, Amondys)
Revenue
$362.93M
▲ 38.9% YoY
Diluted EPS
$0.07
Gross margin
87.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
Confident tone ELEVIDYS commercial performance Financial results and capitalization FDA label expansion review
Revenue
$413.46M
▲ 63.1% YoY
Diluted EPS
$0.37
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
Confident tone ELEVIDYS launch performance Roche ex-US partnership and supply Pipeline advancement
Revenue
$396.78M*
▲ 53.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript
Revenue
$331.82M
▲ 44.1% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
Revenue
$261.24M
▲ 11.9% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript
Revenue
$253.50M
▲ 20.2% YoY
Diluted EPS
$-5.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Call Transcript
Revenue
$258.43M*
▲ 28.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Sarepta Therapeutics, Inc. (SRPT) Q3 2022 Earnings Call Transcript
Revenue
$230.27M
▲ 21.6% YoY
Diluted EPS
$-2.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Sarepta Therapeutics, Inc. (SRPT) Q2 2022 Earnings Call Transcript
Revenue
$233.49M
▲ 42.3% YoY
Diluted EPS
$-2.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2022 Earnings Call Transcript
Revenue
$210.83M
▲ 43.5% YoY
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Sarepta Therapeutics, Inc. (SRPT) Q4 2021 Earnings Call Transcript
Revenue
$201.46M*
▲ 38.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-15
Sarepta Therapeutics, Inc. (SRPT) Q3 2021 Earnings Call Transcript
Revenue
$189.41M
▲ 31.6% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Sarepta Therapeutics, Inc. (SRPT) Q2 2021 Earnings Call Transcript
Revenue
$164.09M
▲ 19.5% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2021 Earnings Call Transcript
Revenue
$146.93M
▲ 29.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Sarepta Therapeutics, Inc. (SRPT) Q4 2020 Earnings Call Transcript
Revenue
$145.14M
▲ 45% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Sarepta Therapeutics, Inc. (SRPT) Q3 2020 Earnings Call Transcript
Revenue
$143.92M
▲ 45.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Sarepta Therapeutics, Inc. (SRPT) Q2 2020 Earnings Call Transcript
Revenue
$137.36M
▲ 45.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Sarepta Therapeutics, Inc. (SRPT) Q1 2020 Earnings Call Transcript
Revenue
$113.67M
▲ 30.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–30 of 30 earnings calls
Key facts CIK 873303 CUSIP 803607100 13F (30d) 9 filings 9 filers Visit website Investor relations